Ipamorelin 10mg

About Ipamorelin 10mg

Ipamorelin (NNC 26-0161) is a synthetic pentapeptide growth hormone secretagogue that acts as a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. Developed by Novo Nordisk in the late 1990s, ipamorelin stimulates growth hormone (GH) release from somatotroph cells in the anterior pituitary gland through direct receptor activation, triggering the Gq/11-phospholipase C signalling cascade that leads to calcium-mediated exocytosis of GH-containing secretory granules.

The defining characteristic of ipamorelin — and the reason it occupies a distinctive position among GH secretagogues — is its selectivity. Unlike earlier compounds such as GHRP-6, GHRP-2, and hexarelin, ipamorelin stimulates GH release without producing significant elevations in cortisol, prolactin, or adrenocorticotropic hormone (ACTH). This narrow endocrine footprint makes it a cleaner pharmacological tool for research, allowing investigators to study GH-mediated effects without the confounding influence of simultaneously altered stress hormone or prolactin levels.

Importantly, ipamorelin appears to augment the natural pulsatile pattern of GH release rather than producing a sustained, non-physiological elevation. This pulsatile profile more closely approximates endogenous GH regulation, which has made the peptide particularly attractive for research models examining GH physiology under conditions that preserve normal secretory dynamics.

Research Summary

The foundational pharmacological characterisation of ipamorelin was established by Raun and colleagues at Novo Nordisk. Their studies in swine and rat models demonstrated that ipamorelin stimulated GH release in a dose-dependent manner comparable to GHRP-6, but without the corresponding increases in ACTH or cortisol that accompanied GHRP-6 administration. This selectivity held even at doses substantially exceeding those required for maximal GH stimulation — a finding that clearly differentiated ipamorelin from its predecessors. In head-to-head comparisons, GHRP-6 and GHRP-2 both elevated cortisol and ACTH at GH-stimulating doses, while hexarelin produced the broadest endocrine disruption of the group. Ipamorelin’s effects remained functionally confined to the somatotroph GH-release mechanism, establishing the selectivity profile that has driven much of its subsequent research interest.

Bone density and skeletal metabolism research represents one of the most developed areas of ipamorelin investigation. Anderson et al. conducted a series of studies using ovariectomised rat models — a well-established model for postmenopausal bone loss — to examine the effects of sustained GH stimulation via ipamorelin on bone mineral content and density. Their findings demonstrated that ipamorelin treatment increased bone mineral density and bone formation markers in these models, with effects attributed to GH-mediated stimulation of IGF-1 production and its downstream effects on osteoblast activity. These skeletal studies are notable because the selectivity of ipamorelin allowed the researchers to attribute the observed bone effects to GH/IGF-1 axis stimulation with greater confidence than would have been possible using less selective secretagogues.

Gastrointestinal motility research has provided another productive line of investigation. Studies have examined ipamorelin’s effects on gut motility in animal models, with particular attention to post-operative ileus — the temporary impairment of gastrointestinal motility that commonly follows abdominal surgery. In these models, ipamorelin administration was associated with accelerated recovery of normal bowel function, an effect consistent with the known expression of GHS-R1a receptors in the gastrointestinal tract. This area of research highlights an important dimension of GHS-R1a agonism beyond pituitary GH release, as ghrelin receptor signalling in the gut plays a role in coordinating gastrointestinal motility patterns independently of its growth hormone-related effects.

The combination of ipamorelin with CJC-1295 (a modified GHRH analogue) has attracted considerable research attention due to the complementary nature of their mechanisms. Ipamorelin acts at the pituitary level through GHS-R1a, while CJC-1295 stimulates GH release through the GHRH receptor — a separate signalling pathway that works synergistically with ghrelin receptor activation. Research into this combination is grounded in the established physiological principle that endogenous GH secretion is regulated by the coordinated action of both GHRH and ghrelin signalling. By engaging both pathways simultaneously, the combination has been investigated as a means of producing a more robust and physiologically coherent GH response than either compound alone.

The pulsatile nature of ipamorelin-stimulated GH release remains a key point of discussion in research contexts. Endogenous GH is secreted in discrete pulses, primarily during sleep and in response to physiological stimuli, and this pulsatile pattern is understood to be important for the downstream biological effects of GH, including its influence on IGF-1 production, body composition, and tissue repair processes. Ipamorelin’s ability to amplify these pulses without flattening them into a sustained elevation distinguishes it from approaches that produce continuous GH exposure, and has informed experimental design in studies seeking to model physiologically relevant GH stimulation.